Results 91 to 100 of about 19,263 (243)

[Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].

, 2022
Kai Shen, Huilei Miao, Yajuan Gao, Xinxin Cao, Daobin Zhou, Wei Su, Jing Li   +6 more
openalex   +2 more sources

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Haematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis   +8 more
doaj   +1 more source

Daratumumab, bortezomib and dexamethasone for previously treated myeloma—Real‐world outcomes for 2545 patients treated in England

British Journal of Haematology, EarlyView.
Sarah L. Lawton, Mark Bishton, Katherine E. Thackray, Emma Kipps, Dean Smith   +4 more
wiley   +1 more source

Steady‐state mobilization with on‐demand plerixafor after CD38 antibody‐based induction in multiple myeloma patients

Transfusion, EarlyView.
Abstract Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding impaired stem cell ...
Maximilian Alexander Röhnert, Anna Seifert, Karolin Trautmann‐Grill, Christoph Röllig, Kristin Zimmer, Katharina Egger‐Heidrich, Marius Bill, Lisa Heberling, Freya Schulze, Matthias Blechschmidt, Malte von Bonin, Martin Bornhäuser, Kristina Hölig, Raphael Teipel   +13 more
wiley   +1 more source

Immune and Pathologic Responses in Patients With Localized Prostate Cancer Who Received Daratumumab (Anti-CD38) or Edicotinib (Csf-1R Inhibitor) [PDF]

, 2023
BACKGROUND: The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs).
Basu, Sreyashi, Chapin, Brian F, Corn, Paul G, Drake, Charles G, Duan, Fei, Espejo, Alexsandra B, Gottardis, Marco, Gu, Ai-Di, Hutnick, Natalie, Jindal, Sonali, Kinder, Michelle, Knoblauch, Roland, Logothetis, Christopher J, Pettaway, Curtis A, Sharma, Padmanee, Siddiqui, Bilal A, Subudhi, Sumit K, Tidwell, Rebecca S S, Troncoso, Patricia, Ward, John F, Yadav, Shalini S   +20 more
core   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Myeloma Treatment on SÄS – Does it conform to good national standard? [PDF]

, 2017
Myeloma Treatment on SÄS – Does it conform to good national standard? Stefan Carslöv Supervisor: Ulf-Henrik Mellqvist Department of Medicine, Södra Älvsborg Hospital, Borås, Sweden Introduction Myeloma has an incidence of approximately 600 patient per ...
Carslöv, Stefan
core  

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients [PDF]

, 2021
Karen Louise Højholt, Henrik Gregersen, Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted   +18 more
openalex   +1 more source

Lenalidomide Plus Dexamethasone as FIRST‐Line Therapy in Transplant‐Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non‐Interventional Study FIRST‐NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objectives Lenalidomide and low‐dose dexamethasone (Rd) is a standard regimen for transplant‐ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM), for whom a multi‐drug treatment regimen is not considered appropriate. While Rd has been intensively investigated in clinical trials, prospective real‐world data are still scarce ...
H. Nückel, T. Behlendorf, H. Schulz, M. Schulze, C. Schardt, T. Medinger, M. Koenigsmann, T. Dechow, M. Indorf, D. Bürkle, V. Engelbertz, J. Rauh, B. Schmidt, A. Sauer, C. Vannier, K. Potthoff   +15 more
wiley   +1 more source